The results of the present study are in partial agreement with a previous single-centre study involving patients with IBD treated with different types of biologic drugs [17]; in both studies, the reduction of IL-6 in course of therapy was associated to the clinical response at 12 months of treatment. The gene discussed is IL6; the disease is inflammatory bowel disease.